The Activate study, conducted by the pharmaceutical company Bial R&D Investments, is a recently-started clinical trial to test a new medication for the treatment of Parkinson’s disease in patients with a GBA1 gene mutation. While participation in this clinical study is very important, it will advance the knowledge of research on Parkinson’s disease, there may be no direct benefit to participants, however this research may benefit others in the future.
News | Research News
A new 3 year grant of $9 million has been awarded! Professor Dario Alessi, Director of the MRC-PPU, said, “This is the opportunity of a lifetime as a Parkinson’s disease researcher”, read more about it here:
Don't miss this new series of free online events from the MJ Fox Foundation - for clinicians, researchers and PwPs: Link to MJFF website to book a place
The next dates are:
15 September - The Many Faces of Parkinsons; and
Funding success for Esther Sammler to explore the connection between the gut and Parkinson’s disease (PD) in man and mice. A connection between the gut and PD has long been recognized: constipation is a common non-motor symptom that often predates the emergence of motor problems and PD diagnosis by decades. The vagal nerve represents a direct connection between the brain stem and the intestinal tract and lends support to the Braak theory that PD might originate in the gut rather than the brain.